Calcipressin 3 (DSCR1L2) Antibody (C-term) Blocking peptide
€363.00
In stock
SKU
AC-BP6317a
Background:
DSCR1L2 inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A, and may play a role during central nervous system development. Highest expression occurs in heart, skeletal muscle kidney, liver and peripheral blood leukocytes.
Other Names:
Calcipressin-3, Down syndrome candidate region 1-like protein 2, Myocyte-enriched calcineurin-interacting protein 3, MCIP3, Regulator of calcineurin 3, RCAN3, DSCR1L2
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6317a was selected from the C-term region of human DSCR1L2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: RCAN3
Gene ID: 11123
Primary Accession: Q9UKA8
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
DSCR1L2 inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A, and may play a role during central nervous system development. Highest expression occurs in heart, skeletal muscle kidney, liver and peripheral blood leukocytes.
Other Names:
Calcipressin-3, Down syndrome candidate region 1-like protein 2, Myocyte-enriched calcineurin-interacting protein 3, MCIP3, Regulator of calcineurin 3, RCAN3, DSCR1L2
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6317a was selected from the C-term region of human DSCR1L2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: RCAN3
Gene ID: 11123
Primary Accession: Q9UKA8
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review